UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 130

Sortiert nach

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Frontiers in immunology, 2020-12, Vol.11, p.599417-599417

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Clinical and translational science, 2021-11, Vol.14 (6), p.2132-2138

2021

Link zum Volltext

Verfügbarkeit prüfen

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Scientific reports, 2022-11, Vol.12 (1), p.19067-7, Article 19067

2022

Link zum Volltext

Verfügbarkeit prüfen

Lack of Effect of Cenerimod, a Selective S1P1 Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive

International journal of molecular sciences, 2022-11, Vol.23 (23), p.14986

2022

Link zum Volltext

Verfügbarkeit prüfen

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis

Journal of dermatological science, 2018-02, Vol.89 (2), p.136-145

2018

Link zum Volltext

Verfügbarkeit prüfen

Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects

International journal of molecular sciences, 2019-07, Vol.20 (13), p.3232

2019

Link zum Volltext

Verfügbarkeit prüfen

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

Scientific reports, 2020-03, Vol.10 (1), p.4410, Article 4410

2020

Link zum Volltext

Verfügbarkeit prüfen

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Nature medicine, 2007-02, Vol.13 (2), p.150-155

2007

Link zum Volltext

Verfügbarkeit prüfen

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

Orphanet journal of rare diseases, 2020-10, Vol.15 (1), p.1-15, Article 303

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

Clinical and translational science, 2023-07, Vol.16 (7), p.1220-1231

2023

Link zum Volltext

Verfügbarkeit prüfen

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists

Biomolecules (Basel, Switzerland), 2023-09, Vol.13 (9), p.1365

2023

Link zum Volltext

Verfügbarkeit prüfen

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel

Clinical and translational science, 2022-08, Vol.15 (8), p.1906-1915

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects

International journal of molecular sciences, 2017-12, Vol.18 (12), p.2636

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects

Clinical and translational science, 2021-01, Vol.14 (1), p.143-147

2021

Link zum Volltext

Verfügbarkeit prüfen

Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans

Clinical and translational science, 2024-02, Vol.17 (2), p.n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Drug Development for Pediatric Populations: Regulatory Aspects

Pharmaceutics, 2010-11, Vol.2 (4), p.364-388

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel

Clinical and translational science, 2020-09, Vol.13 (5), p.886-890

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders

Clinical and translational science, 2021-03, Vol.14 (2), p.558-567

2021

Link zum Volltext

Verfügbarkeit prüfen

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist

Pharmacology research & perspectives, 2023-08, Vol.11 (4), p.e01112-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan

Clinical and translational science, 2019-09, Vol.12 (5), p.440-444

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Allergy, asthma, and clinical immunology, 2017-04, Vol.13 (1), p.18-18, Article 18

2017

Link zum Volltext

Verfügbarkeit prüfen

The orexin story and orexin receptor antagonists for the treatment of insomnia

Journal of sleep research, 2023-12, Vol.32 (6), p.e13902-e13902

2023

Link zum Volltext

Verfügbarkeit prüfen

Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment

Chest, 2012-10, Vol.142 (4), p.826A-826B

2012

Link zum Volltext

Verfügbarkeit prüfen

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

Antiviral therapy, 2010, Vol.15 (2), p.157-163

2010

Link zum Volltext

Verfügbarkeit prüfen

Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment

Chest, 2012-10, Vol.142 (4), p.830A-830B

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 130

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology & Pharmacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(127)
Tagungsberichte
(3)

Sprache

Englisch
(130)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Lack of Effect of Cenerimod, a Selective S1P1 Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis

Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development

Promotion of sleep by targeting the orexin system in rats, dogs and humans

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects

Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans

Drug Development for Pediatric Populations: Regulatory Aspects

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist

Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

The orexin story and orexin receptor antagonists for the treatment of insomnia

Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment

Aktive Filter

Suchergebnisse filtern